Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains-Reference-Cited by-同舟云学术

Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains

Published:2017-05-01 Issue:9 Volume:60 Page:4002-4022
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Bouché Léa¹^ORCID,Christ Clara D.¹,Siegel Stephan¹,Fernández-Montalván Amaury E.¹,Holton Simon J.¹,Fedorov Oleg²³,ter Laak Antonius¹,Sugawara Tatsuo¹,Stöckigt Detlef¹,Tallant Cynthia²³,Bennett James²³,Monteiro Octovia²³,Díaz-Sáez Laura²³,Siejka Paulina²³,Meier Julia²,Pütter Vera¹,Weiske Jörg¹,Müller Susanne²³,Huber Kilian V. M.²³,Hartung Ingo V.¹,Haendler Bernard¹

Affiliation:

1. Drug Discovery, Bayer AG, Müllerstrasse 178, 13353 Berlin, Germany

2. Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, U.K.

3. Target Discovery Institute, Nuffield Department of Clinical Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00306

Reference74 articles.

1. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains